Exploring the Characteristics of Intestinal Microbiota in Hematologic Malignancy Patients via 16s rDNA High-Throughput Sequencing.

BACKGROUND: Malignant hematopathy is an important branch of malignant tumors, with high mortality and malignancy. The purpose of this study was to investigate the relationship between intestinal microecology and diseases by observing patients with newly diagnosed hematologic malignancy. METHODS: In this study a total of 23 stool samples were collected and analyzed, 13 of which were stool samples from newly diagnosed patients with malignant blood system diseases, and 10 were healthy individual controls. The characteristics of the intestinal flora were analyzed through 16s rDNA technology in the next-generation sequenc-ing (NGS). RESULTS: Bacteroidetes and Firmicutes accounted for the major abundance of the intestinal microecology in both patients with hematological malignancies and healthy controls, whereas the abundance of Bacteroidetes in the patient group was lower than that in healthy controls. Linear discriminant analysis (LDA) in LEfSa was used to search for landmark species, suggesting that Erysipelotrichi, Erysipelotrichales, and Erysipelotrichaceae could be considered as markers for patients with hematological malignant diseases. Butyricicoccus pullicaecorum, Bacteroides plebeius, and Collinsella aerofaciens also contribute to potential values as markers for intestinal flora in hematological malignant patients. CONCLUSIONS: Patients with hematologic malignancies have altered intestinal flora structure compared with healthy individuals, which can provide new ideas for the treatment of hematologic malignancies.

Temperature-insensitive laser frequency stabilization to molecular absorption edge using an acousto-optic modulator.

A temperature-insensitive edge laser frequency stabilization method with an acousto-optic modulator (AOM) was proposed and demonstrated both theoretically and experimentally in this Letter. In the method, in addition to the unshifted laser frequency, two other shifted frequencies were generated by the AOM. The intensity ratio of these two shifted frequencies was used to stabilize the laser. As the intensity ratio was nearly constant despite the temperature change, the proposed method was temperature insensitive. The theoretical and experimental results showed that the frequency drift of a stabilized laser induced by temperature change was reduced by more than 2 orders of magnitude by using the proposed method when compared with traditional frequency stabilization without an AOM.

A System Bioinformatics Approach Predicts the Molecular Mechanism Underlying the Course of Action of Radix Salviae Reverses GBM Effects.

OBJECTIVE: This study used in vitro techniques to investigate the therapeutic effect of Radix Salviae on human glioblastoma and decode its underlying molecular mechanism. METHODS: The active components and targets of the Radix Salviae were identified from the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP). The targets of human glioblastoma were obtained from the GeneCards Database. The Radix Salviae-mediated antiglioblastoma was evaluated by Gene Ontology (GO) analyses and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. Finally, mechanism of action of Radix Salviae against human glioblastoma was deduced by molecular docking and experiments. RESULTS: We screened 66 active ingredients and 45 targets of the Radix Salviae. The enrichment analysis based on the targets mentioned above suggested a possible role in protein phosphorylation, cell transcription, apoptosis, and inflammatory factor signaling pathways. Further study demonstrated that cryptotanshinone, an essential component of Radix Salviae, played a significant role in killing human glioblastoma cells and protecting the body by inhibiting the AKT, IKB, and STAT3 signaling pathways. CONCLUSIONS: Radix Salviae could inhibit the proliferation and invasion of human glioblastoma by regulating STAT3, Akt, and IKB signaling pathways. Radix Salviae has potential therapeutic value in the future for human glioblastoma.